Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption

Cancer Research

Volumn 58, Issue 3, 1998, Pages 462-467

  Sasaki, Akira ^a   Alcalde, Rafael E ^a   Nishiyama, Akiyoshi ^a   Lim, Darwin D ^a   Mese, Hiroshi ^a   Akedo, Hitoshi ^b   Matsumura, Tomohiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANGIOGENESIS INHIBITOR; CALCITRIOL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CULTURE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CACHEXIA; CALCITRIOL; CELLS, CULTURED; CYCLOHEXANES; DISEASE MODELS, ANIMAL; FEMALE; HEART VENTRICLES; HUMANS; INJECTIONS; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM CIRCULATING CELLS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; OSTEOLYSIS; SESQUITERPENES; TUMOR CELLS, CULTURED;

EID: 0032005932     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Body, J. J. Metastatic bone disease. Clinical and therapeutic aspects. Bone, 13 (Suppl. 1): S57-S62, 1992.
2. Yoneda, T., Sasaki, A., and Mundy, G. R. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat., 32: 73-84, 1994.
3. Coleman, R. E., and Rubens, R. D. The clinical course of bone metastases from breast cancer. Br. J. Cancer, 55: 61-66, 1987.
4. Galasko, C. S. B. Mechanisms of bone destruction in the development of skeletal metastases. Nature (Lond.), 263: 507-508, 1976.
5. Mundy, G. R. Mechanisms of osteolytic bone destruction. Bone, 12 (Suppl. 1): S1-S6, 1991.
6. Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, G. D., Mundy, G. R., and Boyce, B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res., 10: 1478-1487, 1995.
7. Sasaki, A., Boyce, B. F., Story, B., Wright, K. R., Chapman, M., Boyce, R., Mundy, G. R., and Yoneda, T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 55: 3551-3557, 1995.
8. Yoneda, T., Sasaki, A., Dunstan, C., Williams, P., Bauss, F., De Clerck, Y. A., and Mundy, G. R. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate Ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest., 99: 2509-2517, 1997.
9. Folkman, J. What is the evidence that tumors and angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
10. Relf, M., Le Jeune, S., Scott, P. A. E., Fox, S., Smith, K., Leel, R., Moghaddam, A., Whitehouse, R., Bicknell, R., and Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.
11. Alcalde, R. E., Terakado, N., Otsuki, K., and Matsumura, T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology, 54: 324-328, 1997.
12. Abrams, J. S., Moore, T. D., and Friedman, M. New chemotherapeutic agents for breast cancer. Cancer, 74 (Suppl. 3): 1164-1176, 1994.
13. Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA, 93: 2002-2007, 1996.
14. Mori, Y., Hiraki, Y., Kondo, J., Nakamaru, Y., Miyazawa, H., Shiokawa, M., Hiroi, M., Yuasa, T., Kameda, T., Mano, H., Hakeda, S., Kurokawa, T., Suzuki, F., and Kumegawa, M. Breast cancer promotes the bone resorption through the production of angiogenin. 14th Annual meeting of Japanese Society for Bone and Mineral Research, Jpn. J. Bone Miner. Res., 14 (Abstract): 177, Osaka, Japan, 1996.
15. Hiraga, T., Shiraishi, S., Nakajima, T., and Ozawa, H. Vascular endothelial growth regulates bone metabolism in human bone metastasis. 18th Annual meeting of American Society for Bone and Mineral Research, J. Bone Miner. Res., 11(Suppl. 1): S480, Seattle, WA, 1996.
16. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Bern, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.), 348: 555-557, 1990.
17. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer, 69: 212-216, 1994.
18. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53: 5233-5236, 1993.
19. Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., and Fujita, T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res., 53: 4262-4267, 1993.
20. Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res., 53: 2566-2570, 1993.
21. Konno, H., Tanaka, T., Kanai, T., Maruyama, K., Nakamura, S., and Baba, S. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer (Phila.), 77: 1736-1740, 1996.
22. Tanaka, H., Taniguchi, H., Mugitani, T., Koishi, Y., Masuyama, M., Higashida, T., Koyama, H., Suganuma, Y., Miyata, K., Takeuchi, K., and Takahashi, T. Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br. J. Cancer, 72: 650-653, 1995.
23. Mbalaviele, G., Dunstan, C. R., Sasaki, A., Williams, P. J., Mundy, G. R., and Yoneda, T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res., 56: 4063-4070, 1996.
24. Cailleau, R., Yong, R., Olive, M., and Reeves, W. J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst., 53: 661-674, 1974.
25. Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., Boyde, A., and Suda, T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology, 122: 1373-1388, 1988.
26. Boyce, B. F., Aufdemorte, T. B., Garrett, I. R., Yates, A. J. P., and Mundy, G. R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology, 125: 1142-1150, 1989.
27. Nakai, M., Mundy, G. R., Williams, P. J., Boyce, B. F., and Yoneda, T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res., 52: 5395-5399, 1992.
28. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
29. Mundy, G. R. Bone resorting cells. In: M. J. Favus (ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, pp. 16-23. Philadelphia: Lippincott-Raven, 1996.
30. Udagawa, N., Takahashi, N., Akatsu, T., Sasaki, T., Yamaguchi, A., Kodama, H., Martin, T. J., and Suda, T. The bone marrow-derived stromal cell lines MC3T3-G2/ PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology, 125: 1805-1813, 1989.
31. Formigli, L., Orlandini, S. Z., Benvenuti, S., Masi, L., Pinto, A., Gattei, V., Bernabei, P. A., Robey, P. G., Collin-Osdoby, P., and Brandi, M. L. In vitro structural and functional relationships between preosteoclastic and bone endothelial cells: a juxtacrine model for migration and adhesion of osteoclast precursors. J. Cell. Physiol., 162: 199-212, 1995.
32. Zaidi, M., Alam, A. S., Bax, B. E., Shankar, V. S., Bax, C. M. R., Gill, J. S., Pazianas, M., Huang, C. L. H., Sahinoglu, T., Moonga, B. S., Stevens, C. R., and Blake, D. R. Role of the endothelial cell in osteoclast control: new perspective. Bone, 14: 97-102, 1993.
33. Midy, V., and Plouet, J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem. Biophys. Res. Commun., 199: 380-386, 1994.
34. Gagliardi, A., Hadd, H., and Collins, D. S. Inhibition of angiogenesis by suramin. Cancer Res., 52: 5073-5075, 1992.
35. Yoneda, T., Williams, P., Rhine C., Boyce, B. F., Dunstan, C., and Mundy, G. R. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Res., 55: 1989-1993, 1995.
36. Hauschka, P. V., Manrakos, A. E., Iafrati, M. D., Doleman, S. E., and Klagsbrun, M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem., 261: 12665-12674, 1986.
37. Kudelka, A. P., Levy, T., Verschraegen, C. F., Edwards, C. L., Piamsomboon, S., Termrungruanglert, W., Freedman, R. S., Kaplan, A. L., Kieback, D. G., Meyers, C. A., Jaeckle, K. A., Loyer, E., Steger, E., Mante, R., Mavligit, G., Killian, A., Tang, R. A., Gutterman, J. U., and Kavanagh, J. J. A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res., 3: 1501-1505, 1997.
38. Okada, H., and Toguchi, H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 12: 1-99, 1995.